Biovica International AB (publ) (BIOVIC-B.ST)
SEK 0.94
(3.77%)
SEK 0.94
(3.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 133.72 Million SEK | -95.6% |
| 2022 | 115.54 Million SEK | 75.16% |
| 2021 | 65.96 Million SEK | 44.41% |
| 2020 | 45.68 Million SEK | 19.27% |
| 2019 | 38.3 Million SEK | 25.08% |
| 2018 | 30.62 Million SEK | 16.55% |
| 2017 | 26.27 Million SEK | 27.96% |
| 2016 | 20.53 Million SEK | 50.07% |
| 2015 | 13.68 Million SEK | 20.54% |
| 2014 | 11.35 Million SEK | 38.65% |
| 2013 | 8.18 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 25.12 Million SEK | -42.29% |
| 2023 FY | 5.08 Million SEK | -95.6% |
| 2023 Q3 | 28.69 Million SEK | 2.61% |
| 2023 Q1 | 34.39 Million SEK | -11.52% |
| 2023 Q2 | 27.96 Million SEK | -18.72% |
| 2023 Q4 | 43.52 Million SEK | 51.71% |
| 2022 Q2 | 24.54 Million SEK | 13.45% |
| 2022 FY | 115.54 Million SEK | 75.16% |
| 2022 Q4 | 38.87 Million SEK | 26.63% |
| 2022 Q3 | 30.7 Million SEK | 25.11% |
| 2022 Q1 | 21.63 Million SEK | 3.8% |
| 2021 Q2 | 15.23 Million SEK | 13.06% |
| 2021 FY | 65.96 Million SEK | 44.41% |
| 2021 Q1 | 13.47 Million SEK | 32.56% |
| 2021 Q4 | 20.84 Million SEK | 26.97% |
| 2021 Q3 | 16.41 Million SEK | 7.73% |
| 2020 FY | 45.68 Million SEK | 19.27% |
| 2020 Q2 | 11.82 Million SEK | 10.04% |
| 2020 Q3 | 12.99 Million SEK | 9.96% |
| 2020 Q4 | 10.16 Million SEK | -21.79% |
| 2020 Q1 | 10.74 Million SEK | -1.57% |
| 2019 Q2 | 9.3 Million SEK | 18.1% |
| 2019 Q3 | 10.25 Million SEK | 10.15% |
| 2019 Q1 | 7.88 Million SEK | -15.38% |
| 2019 FY | 38.3 Million SEK | 25.08% |
| 2019 Q4 | 10.91 Million SEK | 6.47% |
| 2018 Q1 | 6.07 Million SEK | 0.26% |
| 2018 FY | 30.62 Million SEK | 16.55% |
| 2018 Q4 | 9.31 Million SEK | 14.23% |
| 2018 Q3 | 8.15 Million SEK | 15.21% |
| 2018 Q2 | 7.07 Million SEK | 16.4% |
| 2017 Q2 | 6.33 Million SEK | 5.78% |
| 2017 Q1 | 5.99 Million SEK | -24.66% |
| 2017 FY | 26.27 Million SEK | 27.96% |
| 2017 Q4 | 6.06 Million SEK | -23.09% |
| 2017 Q3 | 7.88 Million SEK | 24.42% |
| 2016 Q3 | 5.45 Million SEK | 49.23% |
| 2016 FY | 20.53 Million SEK | 50.07% |
| 2016 Q4 | 7.95 Million SEK | 45.65% |
| 2016 Q2 | 3.65 Million SEK | 4.93% |
| 2016 Q1 | 3.48 Million SEK | -7.34% |
| 2015 Q4 | 3.76 Million SEK | 0.0% |
| 2015 Q2 | 2.53 Million SEK | 0.0% |
| 2015 Q1 | 2.53 Million SEK | 0.0% |
| 2015 FY | 13.68 Million SEK | 20.54% |
| 2015 Q3 | 3.76 Million SEK | 48.67% |
| 2014 FY | 11.35 Million SEK | 38.65% |
| 2013 FY | 8.18 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | -198.427% |
| Amniotics AB (publ) | 29.07 Million SEK | -359.968% |
| BioArctic AB (publ) | 89.62 Million SEK | -49.198% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 91.169% |
| Camurus AB (publ) | 1.05 Billion SEK | 87.381% |
| Cantargia AB (publ) | 290.01 Million SEK | 53.892% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -510.742% |
| CombiGene AB (publ) | 44.14 Million SEK | -202.922% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 6.48% |
| Genovis AB (publ.) | 88.19 Million SEK | -51.617% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -16.206% |
| Mendus AB (publ) | 129.13 Million SEK | -3.55% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1739.873% |
| Intervacc AB (publ) | 79.78 Million SEK | -67.603% |
| Kancera AB (publ) | 63.07 Million SEK | -111.998% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -2322.939% |
| LIDDS AB (publ) | 27.75 Million SEK | -381.846% |
| Lipum AB (publ) | 37.3 Million SEK | -258.437% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1743.424% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 1.611% |
| NextCell Pharma AB | -576.01 Thousand SEK | 23314.859% |
| OncoZenge AB (publ) | 15.9 Million SEK | -740.754% |
| Saniona AB (publ) | 1.07 Million SEK | -12316.156% |
| Simris Alg AB (publ) | 38.64 Million SEK | -246.054% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 58.408% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 62.608% |
| Xintela AB (publ) | 57.31 Million SEK | -133.307% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 26.419% |
| Ziccum AB (publ) | 27.87 Million SEK | -379.669% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -812.591% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -372.077% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -715.328% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 56.455% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -213.666% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -656.218% |
| Corline Biomedical AB | 30.16 Million SEK | -343.258% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -130.432% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -60.783% |
| Aptahem AB (publ) | 10.01 Million SEK | -1235.491% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 0.722% |
| Fluicell AB (publ) | 28.61 Million SEK | -367.282% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -575.705% |
| AcouSort AB (publ) | 25.87 Million SEK | -416.78% |
| Abliva AB (publ) | 27.86 Million SEK | -379.875% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 30.893% |
| 2cureX AB (publ) | 36.51 Million SEK | -266.181% |
| I-Tech AB | 40.14 Million SEK | -233.073% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 84.441% |
| Cyxone AB (publ) | 28.21 Million SEK | -373.956% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -22.268% |
| Biosergen AB | 26.8 Million SEK | -398.795% |
| Nanologica AB (publ) | 69.88 Million SEK | -91.34% |
| SynAct Pharma AB | 224.49 Million SEK | 40.435% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -202.703% |
| BioInvent International AB (publ) | 441.4 Million SEK | 69.705% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -458.239% |
| Alzinova AB (publ) | 36.39 Million SEK | -267.409% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 53.849% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1602.106% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -20.564% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -809.673% |